Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: From animal models to a pilot clinical study

IF 12.5 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Science Advances Pub Date : 2025-07-02 DOI:10.1126/sciadv.adv0885

Fei Gong, Liyun Zheng, Jiachen Xu, Yumin Wu, Qiutong Jin, Jiaqi Lu, Zifan Pei, Zhongwei Zhao, Minjiang Chen, Jianfei Tu, Shiji Fang, Weiqian Chen, Kailu Wei, Nailin Yang, Chuntao Gong, Fazong Wu, Yeyu Zhang, Caifang Ni, Liang Cheng, Zhuang Liu, Jiansong Ji

{"title":"Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: From animal models to a pilot clinical study","authors":"Fei Gong, Liyun Zheng, Jiachen Xu, Yumin Wu, Qiutong Jin, Jiaqi Lu, Zifan Pei, Zhongwei Zhao, Minjiang Chen, Jianfei Tu, Shiji Fang, Weiqian Chen, Kailu Wei, Nailin Yang, Chuntao Gong, Fazong Wu, Yeyu Zhang, Caifang Ni, Liang Cheng, Zhuang Liu, Jiansong Ji","doi":"10.1126/sciadv.adv0885","DOIUrl":null,"url":null,"abstract":"<div >Transarterial chemoembolization (TACE) has been extensively used in clinic to treat unresectable hepatocellular carcinoma (HCC). Herein, magnesium microspheres (Mg MSs) were used as embolic devices to enhance lipiodol-mediated TACE. After being dispersed in lipiodol and injected into tumors, Mg MSs would continuously generate hydrogen and magnesium hydroxide, which could neutralize the acidic tumor microenvironment, restore exhausted CD8<sup>+</sup> T cells, reverse immunosuppression, and trigger specific T cell–mediated antitumor responses, synergistically resulting in inhibited tumor growth. As demonstrated in a rabbit orthotopic liver cancer model, artery infusion of Mg MS–dispersed lipiodol offered greatly enhanced therapeutic outcome compared to lipiodol-based or polymeric-bead–based TACE. In a pilot clinical study, among 15 eligible patients with HCC, 11 patients achieved complete response and 3 patients achieved partial responses without unexpected treatment-related adverse events during the 1 to 3 months’ follow-up. The objective response rate of Mg-enhanced TACE was ~93.3% in this small-scale trial, much higher than that of current TACE therapies.</div>","PeriodicalId":21609,"journal":{"name":"Science Advances","volume":"11 27","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.science.org/doi/reader/10.1126/sciadv.adv0885","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Advances","FirstCategoryId":"103","ListUrlMain":"https://www.science.org/doi/10.1126/sciadv.adv0885","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Transarterial chemoembolization (TACE) has been extensively used in clinic to treat unresectable hepatocellular carcinoma (HCC). Herein, magnesium microspheres (Mg MSs) were used as embolic devices to enhance lipiodol-mediated TACE. After being dispersed in lipiodol and injected into tumors, Mg MSs would continuously generate hydrogen and magnesium hydroxide, which could neutralize the acidic tumor microenvironment, restore exhausted CD8⁺ T cells, reverse immunosuppression, and trigger specific T cell–mediated antitumor responses, synergistically resulting in inhibited tumor growth. As demonstrated in a rabbit orthotopic liver cancer model, artery infusion of Mg MS–dispersed lipiodol offered greatly enhanced therapeutic outcome compared to lipiodol-based or polymeric-bead–based TACE. In a pilot clinical study, among 15 eligible patients with HCC, 11 patients achieved complete response and 3 patients achieved partial responses without unexpected treatment-related adverse events during the 1 to 3 months’ follow-up. The objective response rate of Mg-enhanced TACE was ~93.3% in this small-scale trial, much higher than that of current TACE therapies.

Abstract Image

查看原文本刊更多论文

镁微球增强肝细胞癌经动脉化疗栓塞治疗：从动物模型到初步临床研究

经动脉化疗栓塞（TACE）已广泛应用于临床治疗不可切除的肝细胞癌（HCC）。在这里，镁微球（Mg MSs）被用作栓塞装置来增强脂醇介导的TACE。Mg MSs分散在脂醇中注入肿瘤后，会不断生成氢氧化镁，从而中和肿瘤酸性微环境，恢复耗尽的CD8+ T细胞，逆转免疫抑制，触发特异性T细胞介导的抗肿瘤反应，协同抑制肿瘤生长。在兔原位肝癌模型中显示，动脉输注Mg - ms分散的脂醇比基于脂醇或聚合物微球的TACE治疗效果更好。在一项试点临床研究中，在15例符合条件的HCC患者中，在1 - 3个月的随访中，11例患者达到完全缓解，3例患者达到部分缓解，未发生意外的治疗相关不良事件。在这项小规模试验中，mg增强TACE的客观缓解率为~93.3%，远高于目前的TACE治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Science Advances 综合性期刊-综合性期刊

CiteScore

21.40

自引率

1.50%

发文量

1937

审稿时长

29 weeks

期刊介绍： Science Advances, an open-access journal by AAAS, publishes impactful research in diverse scientific areas. It aims for fair, fast, and expert peer review, providing freely accessible research to readers. Led by distinguished scientists, the journal supports AAAS's mission by extending Science magazine's capacity to identify and promote significant advances. Evolving digital publishing technologies play a crucial role in advancing AAAS's global mission for science communication and benefitting humankind.